Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure

Mediators of Inflammation

Volumn 2008, Issue , 2008, Pages

  Elias, Gialafos J ^a   Ioannis, Moyssakis ^a   Theodora, Psaltopoulou ^a   Dimitrios, Papadopoulos P ^a   Despoina, Perea ^a   Kostantinos, Vlasis ^a   Charalampos, Kostopoulos ^a   Vassilios, Votteas ^a   Petros, Sfikakis P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME METABOLISM; FEMALE; HEART PERFORMANCE; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; BLOOD; LUNG FIBROSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; SYSTOLE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY ARTERY; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SYSTOLE; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 59549107575     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2008/164134     Document Type: Article

References (47)

1. Denton C. P., Black C. M., Abraham D. J., Mechanisms and consequences of fibrosis in systemic sclerosis Nature Clinical Practice Rheumatology 2006 2 3 134 144
2. Charles C., Clements P., Furst D. E., Systemic sclerosis: hypothesis-driven treatment strategies The Lancet 2006 367 9523 1683 1691
3. Bull T. M., Screening and therapy of pulmonary hypertension in systemic sclerosis Current Opinion in Rheumatology 2007 19 6 598 603
4. Nagase H., Brew K., Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors Biochemical Society Symposium 2003 70 201 212
5. Koskivirta I., Rahkonen O., Mäyränpää M., Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology Histochemistry and Cell Biology 2006 126 3 335 342
6. Kuroda K., Shinkai H., Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis Archives of Dermatological Research 1997 289 10 567 572
7. Mattila L., Airola K., Ahonen M., Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts Journal of Investigative Dermatology 1998 110 4 416 421
8. Greene J., Wang M., Liu Y. E., Raymond L. A., Rosen C., Shi Y. E., Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4 The Journal of Biological Chemistry 1996 271 48 30375 30380
9. Fielitz J., Leuschner M., Zurbrügg H. R., Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis Journal of Molecular Medicine 2004 82 12 809 820
10. Felkin L. E., Birks E. J., George R., A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support The Journal of Heart and Lung Transplantation 2006 25 12 1413 1419
11. Stratmann B., Farr M., Tschesche H., MMP-TIMP interaction depends on residue 2 in TIMP-4 FEBS Letters 2001 507 3 285 287
12. Williams M. H., Handler C. E., Akram R., Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension European Heart Journal 2006 27 12 1485 1494
13. Sfikakis P. P., Kyriakidis M., Vergos C., Diffusing capacity of the lung and nifedipine in systemic sclerosis Arthritis and Rheumatism 1990 33 11 1634 1639
14. Kostopoulos Ch., Koutsikos J., Toubanakis C., Lung scintigraphy with nonspecific human immunoglobulin G (T99mC -HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) European Journal of Nuclear Medicine and Molecular Imaging 2008 35 2 343 351
15. Moyssakis I., Gialafos E., Vassiliou V., Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement Rheumatology 2005 44 2 251 254
16. Tei C., Dujardin K. S., Hodge D. O., Doppler echocardiographic index for assessment of global right ventricular function Journal of the American Society of Echocardiography 1996 9 6 838 847
17. McQuillan B. M., Picard M. H., Leavitt M., Weyman A. E., Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects Circulation 2001 104 23 2797 2802
18. Mukerjee D., St. George D., Knight C., Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis Rheumatology 2004 43 4 461 466
19. LeRoy E. C., Black C., Fleischmajer R., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis Journal of Rheumatology 1988 15 2 202 205
20. MacGregor A. J., Canavan R., Knight C., Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival Rheumatology 2001 40 4 453 459
21. Giannelli G., Iannone F., Marinosci F., Lapadula G., Antonaci S., The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension Current Medical Research and Opinion 2005 21 3 327 332
22. Trad S., Amoura Z., Beigelman C., Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease Arthritis and Rheumatism 2006 54 1 184 191
23. Li H., Simon H., Bocan T. M. A., Peterson J. T., MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition Cardiovascular Research 2000 46 2 298 306
24. Seeland U., Kouchi I., Zolk O., Itter G., Linz W., Böhm M., Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts Journal of Molecular and Cellular Cardiology 2002 34 2 151 163
25. Bonnema D. D., Webb C. S., Pennington W. R., Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) Journal of Cardiac Failure 2007 13 7 530 540
26. Redfield M. M., Rodeheffer R. J., Jacobsen S. J., Mahoney D. W., Bailey K. R., Burnett J. C. Jr., Plasma brain natriuretic peptide concentration: impact of age and gender Journal of the American College of Cardiology 2002 40 5 976 982
27. Spencer K. T., Kirkpatrick J. N., Mor-Avi V., Decara J. M., Lang R. M., Age dependency of the Tei index of myocardial performance Journal of the American Society of Echocardiography 2004 17 4 350 352
28. Allanore Y., Borderie D., Avouac J., High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis Arthritis and Rheumatism 2008 58 1 284 291
29. Toubi E., Kessel A., Grushko G., Sabo E., Rozenbaum M., Rosner I., The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity Clinical and Experimental Rheumatology 2002 20 2 221 224
30. Yazawa N., Kikuchi K., Ihn H., Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis Journal of the American Academy of Dermatology 2000 42 1, part 1 70 75
31. Giannelli G., Iannone F., Marinosci F., Lapadula G., Antonaci S., Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs European Journal of Clinical Investigation 2006 36 supplement 3 73 77
32. Dziankowska-Bartkowiak B., Waszczykowska E., Zalewska A., Sysa-Jȩdrzejowska A., Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients Mediators of Inflammation 2005 2005 3 144 149
33. Shahin A., Elsawaf A., Ramadan S., Shaker O., Amin M., Taha M., Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities Mediators of Inflammation 2006 2006 6
34. Young-Min S. A., Beeton C., Laughton R., Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls Annals of the Rheumatic Diseases 2001 60 9 846 851
35. Kim W.-U., Min S.-Y., Cho M.-L., Elevated matrix metalloproteinase-9 in patients with systemic sclerosis Arthritis Research and Therapy 2005 7 1 R71 R79
36. Sfikakis P. P., McCune B. K., Tsokos M., Aroni K., Vayiopoulos G., Tsokos G. C., Immunohistological demonstration of transforming growth factor- β isoforms in the skin of patients with systemic sclerosis Clinical Immunology and Immunopathology 1993 69 2 199 204
37. Verrecchia F., Laboureau J., Verola O., Skin involvement in scleroderma: where histological and clinical scores meet Rheumatology 2007 46 5 833 841
38. Han Y.-P., Tuan T.-L., Hughes M., Wu H., Garner W. L., Transforming growth factor- β-and tumor necrosis factor- α -mediated induction and proteolytic activation of MMP-9 in human skin The Journal of Biological Chemistry 2001 276 25 22341 22350
39. Schermuly R. T., Kreisselmeier K. P., Ghofrani H. A., Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension Circulation Research 2004 94 8 1101 1108
40. Bou-Gharios G., Osman J., Black C., Olsen I., Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis Clinica Chimica Acta 1994 231 1 69 78
41. Vieillard-Baron A., Frisdal E., Eddahibi S., Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats Circulation Research 2000 87 5 418 425
42. Briest W., Homagk L., Baba H. A., Cardiac remodeling in erythropoietin-transgenic mice Cellular Physiology and Biochemistry 2004 14 4-6 277 284
43. Tummalapalli C. M., Heath B. J., Tyagi S. C., Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts Journal of Cellular Biochemistry 2001 80 4 512 521
44. Fernández C. A., Moses M. A., Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4 Biochemical and Biophysical Research Communications 2006 345 1 523 529
45. Seeland U., Haeuseler C., Hinrichs R., Myocardial fibrosis in transforming growth factor- β 1 (TGF- β 1) transgenic mice is associated with inhibition of interstitial collagenase European Journal of Clinical Investigation 2002 32 5 295 303
46. Harley I. T. W., Kaufman K. M., Guthridge J. M., Whole genome association by DNA pooling leads to interesting candidate genes for systemic sclerosis Arthritis and Rheumatism 2007 56 S65
47. Sfikakis P. P., Tsokos G. C., Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations Clinical and Experimental Rheumatology 1995 13 6 763 777